Drug intelligence / Profile preview

placebo gel (Naval Aeromedical Research Unit, Dayton)

Development stage: Unknown
Lead developer: Defender Pharmaceuticals
Administration: Intranasal

Overview

This placebo gel is an inactive control used in Phase 3 clinical trials conducted by the Naval Aeromedical Research Unit, Dayton (NAMRU-D) in collaboration with Defender Pharmaceuticals. It was specifically utilized in a randomized, double-blind study to evaluate the efficacy and safety of DPI-386 (an intranasal scopolamine gel) for the prevention and treatment of motion sickness among personnel on ocean-going vessels. The placebo gel is formulated to be physically indistinguishable from the active DPI-386 gel but contains no active pharmaceutical ingredient, serving to establish a baseline for comparing the therapeutic effects of scopolamine.

Other names: placebo nasal gel

Beyond the preview

Go deeper on placebo gel (Naval Aeromedical Research Unit, Dayton).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo gel (Naval Aeromedical Research Unit, Dayton).

Explore the full profile